# reload+after+2024-01-22 20:27:54.652705
address1§4475 Executive Drive
address2§Suite 200
city§San Diego
state§CA
zip§92121
country§United States
phone§858 794 9600
fax§858 794 9605
website§https://calidibio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.
fullTimeEmployees§38
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Allan J. Camaisa', 'age': 63, 'title': 'Chairman of the Board & CEO', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 765818, 'exercisedValue': 0, 'unexercisedValue': 57745496}, {'maxAge': 1, 'name': 'Ms. Wendy  Pizarro Campbell Esq.', 'age': 52, 'title': 'Chief Administrative Officer, Chief Legal Officer, Chief Diversity Officer & Corporate Secretary', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 432077, 'exercisedValue': 0, 'unexercisedValue': 1814122}, {'maxAge': 1, 'name': 'Mr. Andrew C. Jackson', 'age': 54, 'title': 'Chief Financial Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Amish  Patel Ph.D.', 'age': 46, 'title': 'Senior Vice President of Technical Operations', 'yearBorn': 1977, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David  Sans M.B.A., Ph.D.', 'age': 54, 'title': 'Chief Corporate Development', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Boris  Minev M.D., Ph.D.', 'age': 60, 'title': 'President of Medical and Scientific Affairs & Interim Chief Medical Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Stephen  Thesing', 'age': 58, 'title': 'Chief Business Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.424
priceToSalesTrailing12Months§Infinity
currency§USD
dateShortInterest§1702598400
forwardEps§-0.76
exchange§ASE
quoteType§EQUITY
shortName§Calidi Biotherapeutics, Inc.
longName§Calidi Biotherapeutics, Inc.
firstTradeDateEpochUtc§1635773400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§9a7984e0-6061-3b4d-bf45-163ad44f97ec
gmtOffSetMilliseconds§-18000000
targetHighPrice§11.0
targetLowPrice§9.0
targetMeanPrice§10.0
targetMedianPrice§10.0
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§2
quickRatio§0.933
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
